SPIRRIT-HFPEF - DCC

SPIRRIT-HFPEF - DCC

• 批准号: 10018095
• 负责人: Kevin J Anstrom
• 金额: $ 15.6万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-15 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10018095
• 关键词: Adult; Affect; Aldosterone Antagonists; Cardiovascular system; Case Report Form; Cause of Death; Cessation of life; Clinical; Clinical Research; Clinical Trials; Clinical Trials Data Monitoring Committees; Clinical effectiveness; Communities; Community Practice; Complex; Data; Data Coordinating Center; Data Element; Data Set; Development; EFRAC; Electronic Health Record; Elements; Enrollment; Fostering; Goals; Health Care Costs; Healthcare; Heart Arrest; Heart failure; Hospitalization; Intervention; Intervention Trial; Investigation; Leadership; Left Ventricular Ejection Fraction; Life; Michigan; Mineralocorticoid Receptor; Morbidity - disease rate; National Heart, Lung, and Blood Institute; North America; Outcome; Patient Recruitments; Patients; Pharmaceutical Preparations; Placebos; Prevalence; Public Health; Randomized; Randomized Clinical Trials; Randomized Controlled Trials; Registries; Research Institute; Research Personnel; Schedule; South America; Specific qualifier value; Spironolactone; Statistical Data Interpretation; Structure; Sweden; Telephone; Testing; Therapeutic; Therapeutic Intervention; Time; Treatment Efficacy; United States; Universities; University Hospitals; aging population; base; clinical research site; clinically relevant; compliance behavior; cost; data management; data quality; design; effective therapy; evidence base; experience; follow-up; heart function; heart preservation; hospital readmission; improved; mortality; novel; open label; patient population; pragmatic trial; preservation; primary endpoint; primary outcome; prospective; randomized trial; secondary endpoint; secondary outcome; standard of care; symptomatic improvement; tool; treatment as usual

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a pragmatic, registry-based randomized clinical trial that proposes to evaluate the clinical effectiveness of spironolactone versus usual care. The primary hypothesis of SPIRRIT- HFpEF is that treatment with spironolactone will reduce cardiovascular mortality compared with usual care.

螺内酯起始登记治疗心力衰竭的随机干预试验 射血分数 (SPIRRIT-HFpEF) 是一项基于注册的实用随机临床试验，旨在 评估螺内酯与常规护理的临床效果。 SPIRRIT 的主要假设- HFpEF 是指与常规治疗相比，螺内酯治疗可降低心血管死亡率。